Brief: EMA's CHMP Recommends Extension To Marketing Authorisation For Wegovy
22/05/2026 12:01
May 22 (Reuters) - EMA's CHMP: EMA'S CHMP: RECOMMENDED EXTENSION TO MARKETING AUTHORISATION FOR WEGOVY CHMP: RECOMMENDS EXTENSION TO MARKETING AUTHORISATION FOR WEGOVY TO ADD DAILY ORAL TABLET AS ALTERNATIVE FORMULATION TO WEEKLY SUBCUTANEOUS INJECTIONS EMA'S CHMP: RECOMMENDS GRANTING MARKETING AUTHORISATION FOR LIRAGLUTIDE STADA EMA'S CHMP: JASCAYD RECEIVED POSITIVE OPINION FROM CHMP FOR TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS OR PROGRESSIVE PULMONARY FIBROSIS EMA'S CHMP: RECOMMENDS EXTENSION OF THERAPEUTIC INDICATION FOR KEYTRUDA EMA'S CHMP: WITHDRAWAL OF INITIAL MARKETING AUTHORISATION APPLICATION FOR ORBLID AND VEBLOCEMA EMA'S CHMP: RECOMMENDS GRANTING MARKETING AUTHORISATION FOR ETCAMAH EMA'S CHMP: RECOMMENDS EXTENSION OF THERAPEUTIC INDICATION FOR ENHERTU EMA'S CHMP: RECOMMENDS GRANTING MARKETING AUTHORISATION FOR ABLYMICO EMA'S CHMP: RECOMMENDS GRANTING CONDITIONAL MARKETING AUTHORISATION FOR VIJOICE EMA'S CHMP: RECOMMENDS EXTENSION OF THERAPEUTIC INDICATION FOR MAVIRET Further company coverage: [NOVOb.CO] ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Novartis AG
See all newsBrief: Novartis Remind Data At Eaaci Show Rhapsido Potential As First Targeted Therapy For Chronic Inducible Urticaria (Cindu)
Swiss stocks - Factors to watch on June 12
Swiss pharma hub Basel frets over population cap threat
Novartis says rare muscle disease drug shows promise in early trial
Live Markets: Europe at half-time: countdown to the ECB's 'insurance hike'